189 related articles for article (PubMed ID: 24147107)
41. Blocking of stromal interaction molecule 1 expression influence cell proliferation and promote cell apoptosis in vitro and inhibit tumor growth in vivo in head and neck squamous cell carcinoma.
Li P; Bian XY; Chen Q; Yao XF; Wang XD; Zhang WC; Tao YJ; Jin R; Zhang L
PLoS One; 2017; 12(5):e0177484. PubMed ID: 28494008
[TBL] [Abstract][Full Text] [Related]
42. The Influence of Met Receptor Level on HGF-Induced Glycolytic Reprogramming in Head and Neck Squamous Cell Carcinoma.
Boschert V; Klenk N; Abt A; Janaki Raman S; Fischer M; Brands RC; Seher A; Linz C; Müller-Richter UDA; Bischler T; Hartmann S
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31940827
[TBL] [Abstract][Full Text] [Related]
43. Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.
Nakamura Y; Togashi Y; Nakahara H; Tomida S; Banno E; Terashima M; Hayashi H; de Velasco MA; Sakai K; Fujita Y; Okegawa T; Nutahara K; Hamada S; Nishio K
Mol Cancer Ther; 2016 Aug; 15(8):1988-97. PubMed ID: 27207775
[TBL] [Abstract][Full Text] [Related]
44. Mitigation of Tumor-Associated Fibroblast-Facilitated Head and Neck Cancer Progression With Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab.
Kumar D; Kandl C; Hamilton CD; Shnayder Y; Tsue TT; Kakarala K; Ledgerwood L; Sun XS; Huang HJ; Girod D; Thomas SM
JAMA Otolaryngol Head Neck Surg; 2015 Dec; 141(12):1133-9. PubMed ID: 26540318
[TBL] [Abstract][Full Text] [Related]
45. CC-223 inhibits human head and neck squamous cell carcinoma cell growth.
Wang JY; Jin X; Zhang X; Li XF
Biochem Biophys Res Commun; 2018 Feb; 496(4):1191-1196. PubMed ID: 29402408
[TBL] [Abstract][Full Text] [Related]
46. Improved clearance during treatment of HPV-positive head and neck cancer through mTOR inhibition.
Coppock JD; Wieking BG; Molinolo AA; Gutkind JS; Miskimins WK; Lee JH
Neoplasia; 2013 Jun; 15(6):620-30. PubMed ID: 23730210
[TBL] [Abstract][Full Text] [Related]
47. Combined SN-38 and gefitinib treatment promotes CD44 degradation in head and neck squamous cell carcinoma cells.
Nanbu T; Umemura N; Ohkoshi E; Nanbu K; Sakagami H; Shimada J
Oncol Rep; 2018 Jan; 39(1):367-375. PubMed ID: 29192320
[TBL] [Abstract][Full Text] [Related]
48. Neuregulin Signaling Is a Mechanism of Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma.
Baro M; Lopez Sambrooks C; Burtness BA; Lemmon MA; Contessa JN
Mol Cancer Ther; 2019 Nov; 18(11):2124-2134. PubMed ID: 31387891
[TBL] [Abstract][Full Text] [Related]
49. Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma.
Dong G; Chen Z; Li ZY; Yeh NT; Bancroft CC; Van Waes C
Cancer Res; 2001 Aug; 61(15):5911-8. PubMed ID: 11479233
[TBL] [Abstract][Full Text] [Related]
50. Deguelin induces both apoptosis and autophagy in cultured head and neck squamous cell carcinoma cells.
Yang YL; Ji C; Bi ZG; Lu CC; Wang R; Gu B; Cheng L
PLoS One; 2013; 8(1):e54736. PubMed ID: 23372762
[TBL] [Abstract][Full Text] [Related]
51. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
[TBL] [Abstract][Full Text] [Related]
52. A new gamboge derivative compound 2 inhibits cancer stem-like cells via suppressing EGFR tyrosine phosphorylation in head and neck squamous cell carcinoma.
Deng R; Wang X; Liu Y; Yan M; Hanada S; Xu Q; Zhang J; Han Z; Chen W; Zhang P
J Cell Mol Med; 2013 Nov; 17(11):1422-33. PubMed ID: 24112466
[TBL] [Abstract][Full Text] [Related]
53. Multi-Omics Identification of Genetic Alterations in Head and Neck Squamous Cell Carcinoma and Therapeutic Efficacy of HNC018 as a Novel Multi-Target Agent for c-MET/STAT3/AKT Signaling Axis.
Khedkar HN; Chen LC; Kuo YC; Wu ATH; Huang HS
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373393
[TBL] [Abstract][Full Text] [Related]
54. Lysyl oxidase like-4 monoclonal antibody demonstrates therapeutic effect against head and neck squamous cell carcinoma cells and xenografts.
Görögh T; Quabius ES; Heidebrecht H; Nagy A; Muffels T; Haag J; Ambrosch P; Hoffmann M
Int J Cancer; 2016 May; 138(10):2529-38. PubMed ID: 26756583
[TBL] [Abstract][Full Text] [Related]
55. New promising molecular targets in head and neck squamous cell carcinoma.
Bauman JE; Michel LS; Chung CH
Curr Opin Oncol; 2012 May; 24(3):235-42. PubMed ID: 22327839
[TBL] [Abstract][Full Text] [Related]
56. Combined Erlotinib and PF-03084014 treatment contributes to synthetic lethality in head and neck squamous cell carcinoma.
Zheng Y; Wang Z; Ding X; Dong Y; Zhang W; Zhang W; Zhong Y; Gu W; Wu Y; Song X
Cell Prolif; 2018 Jun; 51(3):e12424. PubMed ID: 29232766
[TBL] [Abstract][Full Text] [Related]
57. Osthole induces cell cycle arrest and apoptosis in head and neck squamous cell carcinoma by suppressing the PI3K/AKT signaling pathway.
Yang J; Zhu XJ; Jin MZ; Cao ZW; Ren YY; Gu ZW
Chem Biol Interact; 2020 Jan; 316():108934. PubMed ID: 31870840
[TBL] [Abstract][Full Text] [Related]
58. Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.
Swick AD; Prabakaran PJ; Miller MC; Javaid AM; Fisher MM; Sampene E; Ong IM; Hu R; Iida M; Nickel KP; Bruce JY; Wheeler DL; Kimple RJ
Mol Cancer Ther; 2017 Jul; 16(7):1257-1268. PubMed ID: 28446642
[TBL] [Abstract][Full Text] [Related]
59. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.
Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC
Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469
[TBL] [Abstract][Full Text] [Related]
60. Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384.
Leiker AJ; DeGraff W; Choudhuri R; Sowers AL; Thetford A; Cook JA; Van Waes C; Mitchell JB
Clin Cancer Res; 2015 Jun; 21(12):2792-801. PubMed ID: 25724523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
